Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4801-4810 Newer>

The Motley Fool April 28, 2008 Brian Orelli	FDA Moves Isis' Finish Line The FDA tells drugmaker Isis it must complete cancer tests before submitting its marketing application.
The Motley Fool April 28, 2008 Brian Lawler	Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings.
The Motley Fool April 28, 2008 Brian Lawler	Glaxo Getting By Weakening currency barely redeems the pharmaceutical's Q1 numbers.
The Motley Fool April 28, 2008 Brian Lawler	CV Therapeutics Feels the Love CV Therapeutics announces its second regulatory thumbs-up this month, after its lead drug Ranexa was essentially approved in the European Union.
The Motley Fool April 28, 2008 Brian Lawler	Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results.
Chemistry World April 25, 2008 James Mitchell Crow	Drug Costs Cut on World Malaria Day Swiss pharmaceuticals firm Novartis has announced it will reduce by one fifth the price it charges governments and NGOs for artemisinin-based antimalarial Coartem.
The Motley Fool April 25, 2008 Brian Orelli	Progenics' Double Dose of Good News Its lead drug gets FDA approval and a positive EU recommendation.
The Motley Fool April 25, 2008 Brian Orelli	Affymetrix Learns About Inertia Slower sales of its older chips drag down growth.
The Motley Fool April 25, 2008 Brian Lawler	Vertex Silences the Critics New clinical study data bodes well for Vertex Pharmaceuticals' lead drug.
The Motley Fool April 25, 2008 Brian Lawler	Biogen's Big Step Forward Pharmaceutical company Biogen IDEC boasts better results and a rosier outlook.
<Older 4801-4810 Newer> Return to current articles.